September 15, 2026

Samsung-PolyPeptide Main Offer Opens, Scholar Rock Isembyld SMA, Cogent Bezuclastinib NDA, Amgen MariTide at Morgan Stanley

Samsung-PolyPeptide CHF 1.46B tender main offer opens, Scholar Rock Isembyld SMA launch after FDA approval, Cogent bezuclastinib AdvSM NDA accepted.

6 stories · Covering industry, regulatory

Editor's Note

Tuesday brought the formal opening of the Samsung Biologics tender for PolyPeptide (CHF 44.31 per share net cash, CHF 1.46 billion / approximately $1.8 billion aggregate; main offer period September 15 through October 12, 66⅔% minimum acceptance threshold, Draupnir Holding B.V. already committed with its 55.65% stake) — a peptide-CDMO consolidation that will fold the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint if consummated. Scholar Rock (NASDAQ: SRRK) launched Isembyld (apitegromab-mstn), the first and only muscle-targeted therapy for spinal muscular atrophy, following the September 11 FDA approval for adults and children two years and older already on SMN2-targeted background therapy (Spinraza, Evrysdi, or Zolgensma). Cogent Biosciences announced FDA acceptance of the bezuclastinib NDA in advanced systemic mastocytosis with a PDUFA action date of June 29, 2027, on the strength of the APEX Phase 2 registration trial that reported a 65% overall response rate. Morgan Stanley Global Healthcare Conference Day 2 in New York featured Amgen's Jay Bradner (EVP R&D and AI) and Thomas Dittrich (CFO) plus Ascendis Pharma's leadership on TransCon platform economics after the YUVIWEL launch and reACHin infant sentinel data. STAT News published a landscape piece Tuesday flagging that obesity drugmakers are testing in children as young as six — a topic Novo's STEP Young trial (September 7 readout) already brought into the mainstream conversation.

Industry

Samsung Biologics Tender Offer Main Period Opens Tuesday September 15 for PolyPeptide at CHF 44.31 per Share / CHF 1.46 Billion Total Cash; Draupnir Holding Committed With 55.65% Stake

Samsung Biologics (KRX: 207940), through its direct Swiss subsidiary Samsung Peptide AG, opened Tuesday September 15, 2026 the main offer period for its public tender for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN). Terms: CHF 44.31 net in cash per PolyPeptide share, implied aggregate equity value of approximately CHF 1.46 billion (approximately $1.8 billion at prevailing FX). The main offer period runs September 15 through October 12, 2026 at 4:00 p.m. Central European Time. Closing conditions: 66⅔% minimum acceptance threshold on a fully diluted share count (excluding treasury shares), plus customary regulatory approvals. Draupnir Holding B.V. — PolyPeptide's largest single shareholder with approximately 55.65% of outstanding shares — has committed to tender all of its shares. PolyPeptide's independent directors unanimously recommend acceptance based on an independent fairness opinion from IFBC AG. The price represents a 40% premium to the April 10, 2026 closing price and an 11.6% premium to the 60-day volume-weighted average price prior to the July 20 pre-announcement. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, folding the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint. The transaction consolidates one of the top three global peptide CDMO capacity positions alongside Bachem and CordenPharma.

#samsung-biologics #207940-krx #samsung-peptide-ag #polypeptide-group #ppgn #main-offer-period-opens #september-15-october-12 #chf-44-31-per-share #chf-1-46-billion #usd-1-8-billion #66-2-3-percent-threshold #draupnir-holding #55-65-percent-stake #ifbc-fairness-opinion #peptide-cdmo-consolidation #bachem-cordenpharma-context #end-of-2026-close-target

Regulatory

Scholar Rock Launches ISEMBYLD (Apitegromab-Mstn) as First Muscle-Targeted Therapy for Spinal Muscular Atrophy Following September 11 FDA Approval for Ages 2 and Older on SMN2-Targeted Background

Scholar Rock Inc. (NASDAQ: SRRK) announced Monday September 14, 2026 the commercial launch of ISEMBYLD (apitegromab-mstn) following FDA approval on September 11, 2026 for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are receiving a survival motor neuron 2 (SMN2)-targeted background therapy (Biogen's Spinraza / nusinersen, Novartis's Zolgensma / onasemnogene abeparvovec, or Roche's Evrysdi / risdiplam). ISEMBYLD is a fully human IgG4 monoclonal antibody that binds to promyostatin and latent myostatin (a peptide that limits muscle growth) and inhibits the activation of myostatin, blocking myostatin signaling to preserve and build muscle. The FDA action makes ISEMBYLD the first-and-only muscle-targeted SMA therapy — an addition to rather than a replacement for the SMN2-targeted background therapies that address the underlying survival motor neuron gene deficiency. Approval was based on Phase 3 SAPPHIRE trial data demonstrating motor function improvement (Hammersmith Functional Motor Scale Expanded score) at 12 months versus placebo in patients on stable SMN2-directed therapy. The FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Scholar Rock reported net product sales of $0 (pre-launch) as of Q2 2026 with priced at approximately $310,000 per patient annually.

#scholar-rock #srrk #isembyld #apitegromab-mstn #myostatin-inhibitor #anti-promyostatin-antibody #spinal-muscular-atrophy #sma #fda-approval-september-11 #commercial-launch-september-14 #smn2-background-therapy #spinraza-add-on #evrysdi-add-on #zolgensma-add-on #sapphire-phase-3 #hammersmith-functional-motor-scale #310k-annual-pricing #first-muscle-targeted-sma #peptide-targeted-antibody

Regulatory

Cogent Biosciences Bezuclastinib NDA Accepted by FDA for Advanced Systemic Mastocytosis; June 29, 2027 PDUFA Action Date and No Planned Advisory Committee

Cogent Biosciences (NASDAQ: COGT) announced Tuesday September 15, 2026 that the FDA accepted the New Drug Application (NDA) for bezuclastinib (a selective oral tyrosine kinase inhibitor targeting KIT D816V) in patients with Advanced Systemic Mastocytosis (AdvSM), an aggressive form of the rare hematologic disorder driven by activating mutations in the KIT receptor. FDA assigned a PDUFA target action date of June 29, 2027. The agency communicated that no advisory committee is planned and no potential review issues have been identified. Application support: the APEX Phase 2 registration trial primary endpoint reported a 65% overall response rate per modified International Working Group Myeloproliferative Neoplasms Research and Treatment / European Competence Network on Mastocytosis (mIWG-MRT-ECNM) criteria as of the March 31, 2026 data cutoff, including 57% of patients achieving complete response (CR), CR with partial hematologic recovery (CRh), or partial response (PR) as best response. Cogent had earlier received FDA acceptance for the bezuclastinib NonAdvSM (non-advanced systemic mastocytosis) NDA in March 2026 supported by the SUMMIT Phase 3 trial. Bezuclastinib would compete against Blueprint Medicines' Ayvakit (avapritinib) in the AdvSM segment; both target KIT D816V but Cogent has emphasized bezuclastinib's cleaner off-target profile and better CNS penetration profile.

#cogent-biosciences #cogt #bezuclastinib #kit-d816v-inhibitor #tyrosine-kinase-inhibitor #advanced-systemic-mastocytosis #advsm #nda-accepted-september-15 #june-29-2027-pdufa #apex-phase-2-registration-trial #65-percent-overall-response-rate #57-percent-cr-crh-pr #summit-nonadvsm-context #ayvakit-avapritinib-competitor #non-peptide

Industry

Amgen Presents at Morgan Stanley Global Healthcare Conference Tuesday With Jay Bradner (EVP R&D + AI) and Thomas Dittrich (CFO); MariTide Extended-Dosing Positioning Continues Following Last Week's Wells Fargo Conference

Amgen (NASDAQ: AMGN) presented Tuesday September 15, 2026 at 11:30 a.m. ET at the Morgan Stanley 24th Annual Global Healthcare Conference in New York with Jay Bradner MD (Executive Vice President Research and Development, Artificial Intelligence and Data) and Thomas Dittrich (Executive Vice President and CFO) — an unusual R&D-plus-finance pairing that indicates the AI-driven research investment thesis is a live investor question alongside the near-term MariTide (maridebart cafraglutide, antibody-peptide conjugate combining GLP-1 receptor agonism with GIP receptor antagonism) obesity narrative. The Wells Fargo Healthcare Conference presentation last Thursday September 10 laid out the MariTide dosing thesis (8-week or quarterly maintenance dosing, 4-6 doses per year after induction) plus the MARITIME-SWITCH Phase 3 conversion trial from weekly injectable semaglutide or tirzepatide onto monthly MariTide. Phase 2 data anchored 20% weight loss at 52 weeks plus reductions in triglycerides, hs-CRP, and an 11 mmHg blood pressure drop. Bradner is also expected to address the pipeline consolidation following the August discontinuation of AMG 513 (Phase 1 obesity), which left MariTide as the sole late-stage Amgen obesity asset. Filing is planned late 2026 to early 2027 with anticipated launch 2027-2028.

#amgen #amgn #morgan-stanley-2026-conference #jay-bradner-evp-rd-ai #thomas-dittrich-cfo #maritide #maridebart-cafraglutide #antibody-peptide-conjugate #8-week-quarterly-dosing #maritime-switch #ai-drug-discovery #amg-513-discontinued-context #sole-obesity-asset #phase-3-filing-late-2026-early-2027

Industry

Ascendis Pharma Presents at Morgan Stanley Global Healthcare Conference Tuesday Following ESPE 2026 reACHin Week 52 Infant Data + Wells Fargo Franchise Update

Ascendis Pharma A/S (NASDAQ: ASND) presented Tuesday September 15, 2026 at 8:30 a.m. ET at the Morgan Stanley 24th Annual Global Healthcare Conference in New York in a fireside chat format. The presentation followed the ESPE 2026 congress podium delivery September 8 of first Week 52 sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, marketed as YUVIWEL in the U.S.) in 7 infants with achondroplasia aged 0 to under 2 years: 9.9 cm/year annualized growth velocity, +0.42 ACH-specific supine length Z-score, +3.15 mm sagittal foramen magnum increase, and no decompression surgeries at 100 μg/kg/week dosing. The Ascendis TransCon endocrinology franchise reached €315 million in combined Q2 2026 product revenue (+105% year-over-year): YORVIPATH (palopegteriparatide, PTH replacement) €252 million, SKYTROFA (lonapegsomatropin, growth hormone) €55 million, and YUVIWEL (navepegritide, CNP for achondroplasia) €8 million in the first U.S. commercial quarter. The August 31 Ascendis-BioMarin global settlement resolves the YUVIWEL patent overhang (20% U.S. royalties, 18% EU/South Korea/Brazil through May 2030; ITC Section 337 dismissed).

#ascendis-pharma #asnd #morgan-stanley-2026-conference #navepegritide #transcon-cnp #yuviwel #reachin-week-52 #achondroplasia-infants #espe-2026 #yorvipath-palopegteriparatide #skytrofa-lonapegsomatropin #315-million-q2 #105-percent-yoy-growth #biomarin-settlement #peptide-prodrug

Industry

STAT News Landscape Piece: Obesity Drugmakers Now Testing in Children as Young as Six Following Novo STEP Young Phase 3 Readout September 7

STAT News published Tuesday September 15, 2026 a landscape piece flagging that obesity drug developers have expanded pediatric trial testing to include children as young as six years old, extending the age range down from the Wegovy 12-and-older U.S. label. Novo Nordisk's STEP Young Phase 3 (topline reported September 7) tested once-weekly semaglutide in 165 children aged 6 to under 12 with obesity: 40.4% of the semaglutide group achieved a BMI below the obesity threshold at week 68 versus 0% on placebo, with no new safety concerns and no signals for growth or pubertal development. STAT flagged additional pediatric-obesity trial activity following the January 2023 AAP Clinical Practice Guideline endorsement of medication therapy for children aged 12+ and consideration in ages 6-11. The September 4 Pediatrics journal publication documented a 310-fold increase in GLP-1 prescribing to U.S. children aged 8-11 with obesity between 2019 and mid-2026 (0.03% to 9.3%), with 93.7% of recipients having severe obesity and 65.2% having weight-related comorbidities. Full STEP Young results are scheduled for ObesityWeek 2026 (November 14-17, Washington DC). No Wegovy sNDA for ages under 12 has been filed as of September 15, 2026.

#obesity-pediatric-trials #children-6-to-under-12 #novo-nordisk #step-young-context #stat-news-landscape #aap-2023-guideline #pediatrics-journal-310x #obesityweek-2026-preview #wegovy-pediatric-under-12 #no-snda-filed-yet #glp-1